TMDX Key Statistics, Chart & Performance
The current stock price of TMDX is 130.93 USD. In the past month the price increased by 0.31%. In the past year, price increased by 72.19%.
TMDX Latest News, Press Relases and Analysis
TMDX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.67 | 222.97B | ||
| ISRG | INTUITIVE SURGICAL INC | 65.23 | 201.33B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.84 | 143.55B | ||
| SYK | STRYKER CORP | 27.96 | 140.79B | ||
| IDXX | IDEXX LABORATORIES INC | 57.57 | 58.07B | ||
| BDX | BECTON DICKINSON AND CO | 13.36 | 55.24B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.12 | 49.40B | ||
| RMD | RESMED INC | 25.33 | 36.59B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.66 | 34.82B | ||
| DXCM | DEXCOM INC | 32.38 | 23.62B | ||
| PODD | INSULET CORP | 72.47 | 23.30B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.39 | 18.26B |
Related stock screener links
About TMDX
Company Profile
TransMedics Group, Inc. operates as a commercial stage medical technology company. The company is headquartered in Andover, Massachusetts and currently employs 728 full-time employees. The company went IPO on 2019-05-02. The firm specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. The company also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
Company Info
TRANSMEDICS GROUP INC
200 Minuteman Road
Andover MASSACHUSETTS 01810 US
CEO: Waleed H. Hassanein
Employees: 728
Phone: 19785520900
TRANSMEDICS GROUP INC / TMDX FAQ
Can you describe the business of TRANSMEDICS GROUP INC?
TransMedics Group, Inc. operates as a commercial stage medical technology company. The company is headquartered in Andover, Massachusetts and currently employs 728 full-time employees. The company went IPO on 2019-05-02. The firm specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. The company also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
What is the current price of TMDX stock?
The current stock price of TMDX is 130.93 USD. The price increased by 5.74% in the last trading session.
Does TRANSMEDICS GROUP INC pay dividends?
TMDX does not pay a dividend.
What is the ChartMill rating of TRANSMEDICS GROUP INC stock?
TMDX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Where is TRANSMEDICS GROUP INC (TMDX) stock traded?
TMDX stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for TMDX stock?
The PE ratio for TRANSMEDICS GROUP INC (TMDX) is 53.01. This is based on the reported non-GAAP earnings per share of 2.47 and the current share price of 130.93 USD.
What is the market capitalization of TMDX stock?
TRANSMEDICS GROUP INC (TMDX) has a market capitalization of 4.47B USD. This makes TMDX a Mid Cap stock.
TMDX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to TMDX. When comparing the yearly performance of all stocks, TMDX is one of the better performing stocks in the market, outperforming 92.98% of all stocks.
TMDX Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to TMDX. TMDX has an average financial health and profitability rating.
TMDX Financial Highlights
Over the last trailing twelve months TMDX reported a non-GAAP Earnings per Share(EPS) of 2.47. The EPS increased by 162.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.22% | ||
| ROA | 9.71% | ||
| ROE | 25.88% | ||
| Debt/Equity | 1.43 |
TMDX Forecast & Estimates
19 analysts have analysed TMDX and the average price target is 146.29 USD. This implies a price increase of 11.73% is expected in the next year compared to the current price of 130.93.
For the next year, analysts expect an EPS growth of 162.03% and a revenue growth 39.7% for TMDX